Iqbal Azmi

Iqbal Azmi

Auto-generated profile, based on publicly available information

Iqbal Azmi

Multidisciplinary Center for Advanced Research and Studies, Jamia Millia Islamia, Jamia Nagar, New Delhi, 110025, India

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 September 2022 in Cells
Verified
Journal Article
Open access
PDF file
IFImam Faizan
Imam Faizan
RCRituparna Chaudhuri
Rituparna Chaudhuri
SSShakti Sagar
Shakti Sagar
SASarah Albogami
Sarah Albogami
NCNisha Chaudhary
Nisha Chaudhary
TATanvir Ahmad
Tanvir Ahmad
Circulating cell-free mitochondrial DNA (cf-mtDNA) has been found in the plasma of severely ill COVID-19 patients and is now known as a strong predictor of mortality. However, the underlying mechanism of mtDNA release is unexplored. Here, we show a novel mechanism of SARS-CoV-2-mediated pro-inflammatory/pro-apoptotic mtDNA release and a rational therapeutic stem cell-based approach to mitigate these effects. We systematically screened the effects of 29 SARS-CoV-2 proteins on mitochondrial damage and cell death and found that NSP4 and ORF9b caused extensive mitochondrial structural changes, outer membrane macropore formation, and the release of inner membrane vesicles loaded with mtDNA. The macropore-forming ability of NSP4 was mediated through its interaction with BCL2 antagonist/killer (BAK), whereas ORF9b was found to inhibit the anti-apoptotic member of the BCL2 family protein myeloid cell leukemia-1 (MCL1) and induce inner membrane vesicle formation containing mtDNA. Knockdown of BAK and/or overexpression of MCL1 significantly reversed SARS-CoV-2-mediated mitochondrial damage. Therapeutically, we engineered human mesenchymal stem cells (MSCs) with a simultaneous knockdown of BAK and overexpression of MCL1 (MSCshBAK+MCL1) and named these cells IMAT-MSCs (intercellular mitochondrial transfer-assisted therapeutic MSCs). Upon co-culture with SARS-CoV-2-infected or NSP4/ORF9b-transduced airway epithelial cells, IMAT-MSCs displayed functional intercellular mitochondrial transfer (IMT) via tunneling nanotubes (TNTs). The mitochondrial donation by IMAT-MSCs attenuated the pro-inflammatory and pro-apoptotic mtDNA release from co-cultured epithelial cells. Our findings thus provide a new mechanistic basis for SARS-CoV-2-induced cell death and a novel therapeutic approach to engineering MSCs for the treatment of COVID-19.

7 February 2023 in Viruses
Verified
Journal Article
Open access
PDF file
KIKhursheed Ul Islam
Khursheed Ul Islam
SASaleem Anwar
Saleem Anwar
APAyyub Patel
Ayyub Patel
MMMohammed Tarek Mirdad
Mohammed Tarek Mirdad
MMMahmoud Tarek Mirdad
Mahmoud Tarek Mirdad
JIJawed Iqbal
Jawed Iqbal
Hepatitis C virus (HCV) is a major human pathogen that requires a better understanding of its interaction with host cells. There is a close association of HCV life cycle with host lipid metabolism. Lipid droplets (LDs) have been found to be crucial organelles that support HCV replication and virion assembly. In addition to their role in replication, LDs also have protein-mediated antiviral properties that are activated during HCV infection. Studies have shown that HCV replicates well in cholesterol and sphingolipid-rich membranes, but the ways in which HCV alters host cell lipid dynamics are not yet known. In this study, we performed a kinetic study to check the enrichment of LDs at different time points of HCV infection. Based on the LD enrichment results, we selected early and later time points of HCV infection for global lipidomic study. Early infection represents the window period for HCV sensing and host immune response while later infection represents the establishment of viral RNA replication, virion assembly, and egress. We identified the dynamic profile of lipid species at early and later time points of HCV infection by global lipidomic study using mass spectrometry. At early HCV infection, phosphatidylinositol phospholipids (PIPs), lysophosphatidic acid (LPA), triacyl glycerols (TAG), phosphatidylcholine (PC), and trihexosylceramides (Hex3Cer) were observed to be enriched. Similarly, free fatty acids (FFA), phosphatidylethanolamine (PE), N-acylphosphatidylethanolamines (NAPE), and tri acylglycerols were enriched at later time points of HCV infection. Lipids enriched at early time of infection may have role in HCV sensing, viral attachment, and immune response as LPA and PIPs are important for immune response and viral attachment, respectively. Moreover, lipid species observed at later infection may contribute to HCV replication and virion assembly as PE, FFA, and triacylglycerols are known for the similar function. In conclusion, we identified lipid species that exhibited dynamic profile across early and later time points of HCV infection compared to mock cells, which could be therapeutically relevant in the design of more specific and effective anti-viral therapies.

1 January 2024 in Journal of Nucleic Acids
Verified
Journal Article
Open access
SSSyeda Najidah Shahni
Syeda Najidah Shahni
SASarah Albogami
Sarah Albogami
IAIqbal Azmi
Iqbal Azmi
BPBijay Pattnaik
Bijay Pattnaik
RCRituparna Chaudhuri
Rituparna Chaudhuri
TATanvir Ahmad
Tanvir Ahmad
The development of sensitive and specific diagnostic tools for hepatitis B virus (HBV) and hepatitis C virus (HCV) remains crucial for effective disease management and control. In this study, we utilized CRISPR‐Cas12 and CRISPR‐Cas13 systems for the detection of HBV (DNA virus) and HCV (RNA virus), respectively. We designed and tested multiple guide RNAs (gRNAs) targeting both viruses, confirming successful cleavage of target sequences through gel electrophoresis and a fluorescent reporter assay. Using optimized gRNAs, we developed a lateral flow assay (LFA) for sensitive detection of HBV and HCV, demonstrating a concentration‐dependent signal increase. Importantly, no cross‐reactivity was observed with other viral targets. To further enhance sensitivity, we employed a dual‐enzyme approach, combining Cas12 and Cas13 in a single reaction, which significantly improved detection limits for both viruses. Finally, we developed a dual antigen detection LFA strip capable of simultaneously detecting both HBV and HCV in a single sample. This approach holds promise for point‐of‐care (POC) diagnostics where the specific viral infection is unknown. This study addresses the current limitations in CRISPR‐Cas based diagnostics, namely, the need for ultrasensitive detection methods and the ability to detect multiple antigens using a single test strip. Our findings demonstrate the feasibility of using CRISPR‐Cas systems for highly sensitive and specific detection of HBV and HCV, paving the way for potential POC application.

12 October 2026 in The International Journal of Gastroenterology and Hepatology Diseases
Verified
Journal Article
Closed access
PDF file
KIKhursheed Ul Islam
Khursheed Ul Islam
SASaleem Anwar
Saleem Anwar
MAMd Iqbal Azmi
Md Iqbal Azmi
MNMehwish Nafiz
Mehwish Nafiz
SFShifa Firdous
Shifa Firdous
JIJawed Iqbal
Jawed Iqbal
Introduction: Hepatitis C virus (HCV) research relies heavily on cell culture models because of the limited availability of experimental systems for studying HCV biology and virus-host interactions. Generation of infectious HCV particles in cell culture remains essential for investigating viral replication, pathogenesis, and antiviral responses. However, existing protocols for HCV particle generation using the J6/JFH-1 cDNA clone involve multiple enzymatic treatments and purification steps, which increase DNA loss, reduce RNA recovery, and introduce variability in template preparation. Methods: We developed a simplified workflow for generating HCV particles within the established J6/JFH-1 hepatoma cell culture system. The method utilizes a single compatible buffer system for plasmid linearization and mung bean nuclease treatment, followed by a single DNA purification step to obtain purified J6/JFH-1 and replication-defective JFH-1/ GND plasmid DNA. Plasmid and in vitro transcribed RNA integrity were assessed by agarose gel electrophoresis. Purified RNA was electroporated into Huh7 cells to evaluate viral replication and infectious particle production using RT-qPCR, focus-forming assay, and Western blotting. Results: The optimized workflow produced intact linearized J6/JFH-1 and JFH-1/GND DNA templates and approximately 9.6-kb in vitro-transcribed RNA. J6/JFH-1 RNA produced 2.3 × 106 IU/μl HCV RNA and an infectious titer of 9.5 × 104 FFU/mL, with detectable HCV core protein expression in infected Huh7 cells. In contrast, JFH-1/GND does not produce HCV RNA release and no detectable infectious foci of HCV core protein, which is consistent with its replication-defective phenotype. Discussion: Our study represents a streamlined protocol for template preparation by combining restriction digestion and mung bean nuclease treatment in a compatible buffer system. This workflow simplifies template preparation and reduces intermediate purification steps within the established J6/JFH-1- Huh7 system. Its applicability to other HCV constructs remains to be experimentally validated. Conclusion: This streamlined protocol provides a time-saving and simplified approach for template preparation and infectious J6/JFH-1 particle production within the established Huh7 cell culture system. The workflow was reproducible across independent template preparations and may facilitate HCV studies requiring consistent generation of infectious viral RNA.